423 related articles for article (PubMed ID: 29909605)
41. [Pathogenesis and treatment of anemia in chronic kidney disease].
Nangaku M
Rinsho Ketsueki; 2017; 58(10):1860-1863. PubMed ID: 28978825
[TBL] [Abstract][Full Text] [Related]
42. Investigational therapies for renal disease-induced anemia.
Schmid H; Jelkmann W
Expert Opin Investig Drugs; 2016 Aug; 25(8):901-16. PubMed ID: 27122198
[TBL] [Abstract][Full Text] [Related]
43. An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Drug Saf; 2016 Aug; 15(8):1021-30. PubMed ID: 27149639
[TBL] [Abstract][Full Text] [Related]
44. Anemia in chronic kidney disease.
Atkinson MA; Warady BA
Pediatr Nephrol; 2018 Feb; 33(2):227-238. PubMed ID: 28412770
[TBL] [Abstract][Full Text] [Related]
45. Peginesatide in patients with anemia undergoing hemodialysis.
Fishbane S; Schiller B; Locatelli F; Covic AC; Provenzano R; Wiecek A; Levin NW; Kaplan M; Macdougall IC; Francisco C; Mayo MR; Polu KR; Duliege AM; Besarab A;
N Engl J Med; 2013 Jan; 368(4):307-19. PubMed ID: 23343061
[TBL] [Abstract][Full Text] [Related]
46. Renal anemia: current treatments and emerging molecules.
Heras-Benito M
Rev Clin Esp (Barc); 2023; 223(7):433-439. PubMed ID: 37348652
[TBL] [Abstract][Full Text] [Related]
47. Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia.
Holdstock L; Meadowcroft AM; Maier R; Johnson BM; Jones D; Rastogi A; Zeig S; Lepore JJ; Cobitz AR
J Am Soc Nephrol; 2016 Apr; 27(4):1234-44. PubMed ID: 26494831
[TBL] [Abstract][Full Text] [Related]
48. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.
Akizawa T; Tsubakihara Y; Nangaku M; Endo Y; Nakajima H; Kohno T; Imai Y; Kawase N; Hara K; Lepore J; Cobitz A
Am J Nephrol; 2017; 45(2):127-135. PubMed ID: 27978511
[TBL] [Abstract][Full Text] [Related]
49. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
Kular D; Macdougall IC
Pediatr Nephrol; 2019 Mar; 34(3):365-378. PubMed ID: 29569190
[TBL] [Abstract][Full Text] [Related]
50. Hypoxia-Inducible Factor Stabilizers in End Stage Kidney Disease: "Can the Promise Be Kept?".
Crugliano G; Serra R; Ielapi N; Battaglia Y; Coppolino G; Bolignano D; Bracale UM; Pisani A; Faga T; Michael A; Provenzano M; Andreucci M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830468
[TBL] [Abstract][Full Text] [Related]
51. Consensus commentary and position of the Italian Society of Nephrology on KDIGO controversies conference on novel anemia therapies in chronic kidney disease.
Locatelli F; Del Vecchio L; Esposito C; Gesualdo L; Grandaliano G; Ravera M; ; Minutolo R
J Nephrol; 2024 Apr; 37(3):753-767. PubMed ID: 38705934
[TBL] [Abstract][Full Text] [Related]
52. Roxadustat: Do we know all the answers?
Li QY; Xiong QW; Yao X; Liu F; Tang X; Fu H; Tong T; Mao J; Peng WX
Biomol Biomed; 2023 May; 23(3):354-363. PubMed ID: 36724056
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Therapy for Anemia in Renal Transplantation Patients by Prior Erythropoiesis Stimulating Agent Use.
Nakamura N; Aso S; Nakagawa C; Tachibana M; Fujikawa A; Tsubouchi K; Gunge N; Miyazaki T; Okabe Y; Matsuzaki H; Matsuoka H; Haga N
Transplant Proc; 2023 May; 55(4):829-831. PubMed ID: 37105829
[TBL] [Abstract][Full Text] [Related]
54. The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction.
Nakai T; Saigusa D; Kato K; Fukuuchi T; Koshiba S; Yamamoto M; Suzuki N
Life Sci; 2024 Jun; 346():122641. PubMed ID: 38614299
[TBL] [Abstract][Full Text] [Related]
55. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.
Chen N; Hao C; Peng X; Lin H; Yin A; Hao L; Tao Y; Liang X; Liu Z; Xing C; Chen J; Luo L; Zuo L; Liao Y; Liu BC; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
N Engl J Med; 2019 Sep; 381(11):1001-1010. PubMed ID: 31340089
[TBL] [Abstract][Full Text] [Related]
56. Debate: Are Hydroxylase Inhibitors Stabilizers a Viable Alternative to Erythropoiesis-Stimulating Agents in the Management of Anemia in CKD? CON.
Wish JB
Am J Nephrol; 2022; 53(5):366-371. PubMed ID: 35462360
[No Abstract] [Full Text] [Related]
57. An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease.
Zhao H; Li P; Zhang HL; Jia L
Ren Fail; 2023; 45(2):2258986. PubMed ID: 37724564
[TBL] [Abstract][Full Text] [Related]
58. Cardiac and Kidney Adverse Effects of HIF Prolyl-Hydroxylase Inhibitors for Anemia in Patients With CKD Not Receiving Dialysis: A Systematic Review and Meta-analysis.
Zheng Q; Wang Y; Yang H; Sun L; Zhang P; Zhang X; Guo J; Liu YN; Liu WJ
Am J Kidney Dis; 2023 Apr; 81(4):434-445.e1. PubMed ID: 36396085
[TBL] [Abstract][Full Text] [Related]
59. Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D).
Macdougall IC; Meadowcroft AM; Blackorby A; Cizman B; Cobitz AR; Godoy S; Jha V; Johansen KL; McMahon G; Obrador GT; Wong MG; Singh AK
Am J Nephrol; 2023; 54(1-2):1-13. PubMed ID: 36739866
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of bone marrow findings in hemodialysis patients with erythropoietin-resistant anemia.
Yilmaz M; Karakuş V; Kaya E; İlhanlı N; Huddam B
Ther Apher Dial; 2024 Apr; 28(2):218-224. PubMed ID: 37985009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]